Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
277
resultados
Última actualización
19/08/2026 [06:59:00]
Resultados 175 a 200 de 277
Resumen de: CN122516134A
本发明涉及生物医药技术领域，具体涉及一种植物外囊泡制剂及其制备方法和应用，所述制剂包含植物外囊泡和负载于其上的γ‑氨基丁酸，荧光示踪实验表明，三种外囊泡均能被HT22和SH‑SY5Y神经细胞高效摄取，其中人参外囊泡摄取效率最高；负载实验显示，人参外囊泡对γ‑氨基丁酸的包封率高达75.10%；动物实验证实，口服负载γ‑氨基丁酸的人参外囊泡后，小鼠脑脊液中γ‑氨基丁酸含量显著高于单独使用γ‑氨基丁酸组。本发明有效解决了γ‑氨基丁酸难以穿透血脑屏障的技术问题，为将γ‑氨基丁酸高效递送至中枢神经系统提供了新策略。
Resumen de: CN122516137A
本发明公开一种紫外损伤修复用纳米颗粒的制备方法，通过将卵黄颗粒分散于在碱性环境使其发生溶胀，并在低温高压下均质形成结构疏松的“海绵状”溶胀态，增强颗粒的胶体稳定性和生物利用度，再加入PTS贮备液，在卵黄颗粒和紫檀芪混合同时，施加低频超声，驱动紫檀芪进入卵黄颗粒结构内部，超声结束后将溶液体系pH调回中性，将紫檀芪物理截留于重组的颗粒内部，实现紫檀芪的原位包封，得到紫檀芪分布均匀的EYG‑PTS纳米颗粒。该EYG‑PTS纳米颗粒具有优良抗氧化性能，在紫外线、加热和离子条件下展现出对紫檀芪的优异保护效果，具备很好的保护和修复功效，适用于皮肤防护与修复，可通过静电纺丝技术制备成纳米纤维膜。
Resumen de: CN122516140A
本发明公开了一种黏蛋白‑单宁酸封装白术多糖与干酪乳杆菌的复合物及其制备方法和应用，涉及生物技术领域。所述黏蛋白‑单宁酸封装白术多糖与干酪乳杆菌的复合物为核壳结构，由内至外依次包括益生菌核心、内层包覆层和外层包覆层；所述益生菌为干酪乳杆菌；所述内层包覆层由单宁酸与黏蛋白交联形成；所述外层包覆层为白术多糖。本发明提供的黏蛋白‑单宁酸封装白术多糖与干酪乳杆菌的复合物，可抵御消化道恶劣环境，提升益生菌存活率，靶向定植肠道以抑制沙门氏菌侵袭。其能修复肠道双重屏障、调控机体免疫炎症、恢复仔猪生长性能，无耐药性与药物残留，可安全防控仔猪沙门氏菌感染，养殖应用前景广阔。
Resumen de: CN122516129A
本发明公开了一种包载ABT‑263和ICG的pH/光双响应癌症特异靶向纳米药物递送系统的制备方法及其制备方法：制备PEG‑p (API‑ASP)‑FA、将PEG‑p (API‑ASP)‑FA和ABT‑263和ICG通过薄膜分散‑超声水化法自组装，制得FNPAI。FNPAI通过叶酸介导的主动靶向在肝癌部位富集，在酸性肿瘤微环境中释放ABT‑263诱导线粒体凋亡，近红外光照射ICG产生过量ROS并降低Mcl‑1水平，最终触发癌细胞免疫原性细胞死亡。本发明的FNPAI抗肿瘤效果显著，在近红外光照射下，对肿瘤细胞有明显的抑制作用，并且在动物模型中也表现出良好的抗癌效果，具有良好的临床转化潜力。
Resumen de: CN122516347A
本发明提供了一种靶向抗原提呈细胞的纳米佐剂的制备方法和应用，涉及生物医药技术领域。该靶向抗原提呈细胞的纳米疫苗佐剂，以甘露聚糖和/或其衍生物与金属离子化合物复合形成纳米粒，纳米粒的平均粒径为50‑500 nm。本发明，设计开发的新型疫苗佐剂具有纳米佐剂优势并具有抗原提呈细胞靶向性能。能够在维持良好安全性的同时，显著提升抗原递送效率和交叉呈递能力，全面激发体液和细胞免疫反应，为突破复杂传染病及肿瘤疫苗的研发瓶颈提供关键的解决方案。
Resumen de: CN122516349A
本申请涉及一种乏氧缓释型抗血管内皮生长因子‑白蛋白纳米药物，其中，纳米药物，由抗血管内皮生长因子活性成分、白蛋白和乏氧响应性交联剂制备而成，所述纳米药物为粒径为50‑500nm的交联纳米结构。该纳米药物通过“物理屏障”和“化学开关”的双重机制，实现了对视网膜新生血管疾病的精准、长效和安全治疗。50‑500nm的粒径范围使纳米粒难以穿透血眼屏障，从而有效滞留于眼内，形成局部高药物浓度，同时极大降低了药物进入血液循环的风险。其中的乏氧响应性交联剂在正常氧分压下保持稳定，而在视网膜病变特有的缺血缺氧微环境中，其化学键（如偶氮键）可被特异性还原断裂，触发纳米结构解体并释放药物，实现了“按需”和“靶向”释放。
Resumen de: WO2025100828A1
The present invention relates to a novel ionizable lipid and a lipid nanoparticle composition using same. Lipid nanoparticles formed using the novel ionizable lipid exhibit an excellent gene encapsulation rate and intracellular/in vivo gene delivery rate, and exhibit excellent muscle delivery of genes through local injection, and thus can be effectively used as a composition for drug delivery.
Resumen de: US20260226094A1
0000 The present invention provides, in part, sterol-based cationic lipids with aromatic head groups of Formula (I), and sub-formulas thereof:
0000
0000 or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Resumen de: US20260224688A1
Provided herein are a class of helper lipid compounds of use in the in vivo delivery of therapeutic agents, such as nucleic acids.
Resumen de: US20260225889A1
The invention relates to a method for preparing gels with improved mechanical properties, and to components useful in the manufacture of such a gel, and to the manufacture of such components. The gels are robust to mechanical attack and destructive shear, and comprise spherical nanoparticles.
Resumen de: US20260224507A1
0000 The present disclosure relates to lipid nanoparticles including a lipid layer, a cell-penetrating peptide conjugated to the lipid layer, a collagen-targeting peptide conjugated to the lipid layer and a nucleic acid associated with a vascular disease or condition. The present disclosure also relates to methods of making and using the described lipid nanoparticles for treating vascular disease.
Resumen de: WO2026165156A1
The application is related to compounds of Formula (I), their uses and lipid nanoparticle formulations.
Resumen de: US20260224736A1
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., HSC), and methods of making and using such lipids and targeted lipid. nanoparticles.
Resumen de: US20260224733A1
0000 Nanoparticles comprising an outer surface covalently conjugated to 1,4-Bis(1,4,8,11-tetraazacyclotetradecan-1-yl)methylbenzene (AMD3100) or a derivative thereof capable of binding to C-X-C chemokine receptor type 4 (CXCR4) are provided. Methods for of treating a CXCR4 positive cancer, such as multiple myeloma or acute myeloid leukemia, in a subject in need thereof, methods of determining suitability for treatment and methods of covalently linking a molecule comprising a secondary amine to a lipid nanoparticle, are also provided.
Resumen de: US20260224499A1
A method of treating a pulmonary condition in a subject having or at risk of having the pulmonary condition generally includes administering to the subject a therapeutic composition in an amount effective to treat the pulmonary′ condition. Generally, the therapeutic composition includes purified exosome product (PEP) exosomes and a pharmaceutically acceptable carrier. In one or more embodiments, the PEP exosomes are modified to include at least one exogenous active agent. In one or more embodiments, the therapeutic composition is formulated for delivery directly to a potion of tire pulmonary tract.
Resumen de: US20260224741A1
0000 The present disclosure provides a method for delivery of nucleic acid encoding a chimeric antigen receptor (CAR) for expression by a monocyte and/or macrophage to bind a receptor on a target cell or molecule in vivo, the method comprising contacting a lipid nanoparticle encapsulating the nucleic acid encoding the CAR with the immune cell ex vivo or in vivo, thereby causing cellular uptake of the nucleic acid to cause the immune cell to express the CAR. Further provided is a lipid nanoparticle for use in such method, the lipid nanoparticle having between 20 mol % and 70 mol % of a neutral or zwitterionic amphipathic lipid having a net-neutral charge at physiological pH, an ionizable cationic lipid, and optionally a sterol. The lipid nanoparticle is substantially uncharged at physiological pH and has an apparent pKa of between 6.0 and 7.5. The CAR provides a therapeutic, prophylactic or ameliorative effect in vivo.
Resumen de: AU2025211015A1
The present disclosure provides compositions which facilitate preferential targeting or delivery of a therapeutic agent to a particular organ, cell, or tissue. The presently disclosed compositions comprise lipid nanoparticles formed from a covalent-bond forming lipid, a cationic lipid, and, in some embodiments, a steroid or sterol, a phospholipid, and a PEG lipid.
Resumen de: AU2024419247A1
The present invention relates to a surface-modified albumin nano-platform, a method for preparing same, and a composition for diagnosing or treating a disease using same. The surface-modified albumin nano-platform according to the present invention can reduce ingestion by the reticuloendothelial system even when an excess amount of click-functional groups and various delivery substances are conjugated to albumin, by inactivating a click reaction functional group to which a delivery substance on the surface of albumin is not bound, so that the in vivo half-life is greatly increased, and a target molecule or an active substance can be effectively delivered to a target tissue or cell, leading to excellent therapeutic and diagnostic effects.
Resumen de: US20260226481A1
Provided herein is a method of making circular RNA, a method of isolating circular RNA and compositions comprising circular RNA.
Resumen de: US20260224533A1
The invention relates to a composition comprising or essentially consisting of (i) nanoparticles comprising or essentially consisting of Enzalutamide in crystalline form and (ii) one or more physiologically acceptable polymers and/or copolymers. The invention also relates to processes for the preparation of such compositions, pharmaceutical dosage forms comprising or made from such compositions, and uses of such pharmaceutical dosage forms for medical purposes.
Resumen de: US20260224738A1
A micelle nanoparticle includes a biopolymer-hemin complex in which a hydrophilic biopolymer and hydrophobic hemin are combined. The nanoparticle has a core-shell structure formed by the self-assembly of the polymer-hemin complex. In the core-shell structure, the hydrophobic hemin forms a core and the hydrophilic biopolymer forms a shell. The micelle nanoparticle has excellent catalase- and superoxide dismutase-like activities, the micelle nanoparticle may effectively treat, alleviate and/or prevent inflammatory diseases.
Resumen de: US20260224746A1
Provided herein are compositions and methods for treating musculoskeletal fibrosis and/or scarring by ablating intracellular signaling through specific cell surface receptors through genetic editing. In some aspects, the compositions and methods are directed to the TGFB 1 ligand. In other aspects, the compositions and methods are directed to the TGFB1 receptors (TGFBR1/TGF-BR2). In some aspects, the compositions and methods are to treat or prevent post-trauma fibrosis and/or scarring. In some aspects, the compositions and methods are to treat or prevent postoperative fibrosis and/or scarring. In some aspects, the compositions and methods are for treating or preventing localized nociception, inflammation, degeneration, or morphological changes associated with fibrosis and/or scarring. In some aspect, the compositions and methods are for treating fibrosis.
Resumen de: US20260224694A1
The present invention provides fusion proteins of gE and gI (or variants thereof) that can be used for preventing or treating varicella-zoster virus infection, and use of such fusion proteins (or variants thereof).
Resumen de: US20260224485A1
Disclosed is a composition comprising: particles comprising one or more metals and hydrolysable silicon; one or more lipids; and an active pharmaceutical ingredient (API). Also disclosed are related products, methods and uses.
Nº publicación: US20260224735A1 06/08/2026
Solicitante:
ARIZ PREC MEDICINE INC [US]
ARIZ PRECISION MEDICINE, INC.
Resumen de: US20260224735A1
Inhibitory RNA molecules and specifically targeted compositions that specifically inhibit mammalian PRDM expression, with therapeutic effect in cell proliferative diseases, such as cancer.
BOPI
Sede Electrónica
